Search

Your search keyword '"Nav1.7"' showing total 649 results

Search Constraints

Start Over You searched for: Descriptor "Nav1.7" Remove constraint Descriptor: "Nav1.7"
649 results on '"Nav1.7"'

Search Results

Catalog

Books, media, physical & digital resources

4. Small molecule targeting Na V 1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model.

5. Optimizing Nav1.7‐Targeted Analgesics: Revealing Off‐Target Effects of Spider Venom‐Derived Peptide Toxins and Engineering Strategies for Improvement.

6. SCN9A and SCN10A Polymorphism and Therapeutic Effectiveness of Lidocaine Local Anesthetic Injection in Subjects with Diabetic Neuropathy Pain.

7. Small Fiber Neuropathy in Burning Mouth Syndrome: A Systematic Review.

8. Cannabigerol Reduces Acute and Chronic Hypernociception in Animals Exposed to Prenatal Hypoxia-Ischemia.

9. ST‐2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non‐human primates.

10. Therapeutic targeting of voltage-gated sodium channel NaV1.7 for cancer metastasis.

11. Intranasal CRMP2-Ubc9 inhibitor regulates NaV1.7 to alleviate trigeminal neuropathic pain.

12. Role of macrophages in trigeminal ganglia in ectopic orofacial pain associated with pulpitis.

13. Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine.

14. Therapeutic targeting of voltage-gated sodium channel NaV1.7 for cancer metastasis

15. Role of voltage-gated sodium channels in axonal signal propagation of trigeminal ganglion neurons after infraorbital nerve entrapment

16. Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs

17. Differential expression of slow and fast-repriming tetrodotoxin-sensitive sodium currents in dorsal root ganglion neurons.

18. Genetic, electrophysiological, and pathological studies on patients with SCN9A‐related pain disorders.

19. Neuropilin-1 is essential for vascular endothelial growth factor A–mediated increase of sensory neuron activity and development of painlike behaviors.

20. Ih current stabilizes excitability in rodent DRG neurons and reverses hyperexcitability in a nociceptive neuron model of inherited neuropathic pain.

21. A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials

22. Pathogenetic role of the pain threshold Hypothetical therapeutic perspectives based on the use of drugs to elevate it

23. Identification and targeting of a unique NaV1.7 domain driving chronic pain.

24. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

25. Targeting the vascular endothelial growth factor A/neuropilin 1 axis for relief of neuropathic pain.

26. The β3‐subunit modulates the effect of venom peptides ProTx‐II and OD1 on NaV1.7 gating.

27. Voltage-Gated Sodium Channel Na V 1.7 Inhibitors with Potent Anticancer Activities in Medullary Thyroid Cancer Cells.

28. 一种来源于蜘蛛毒液的新型Nav1.7 多肽抑制剂的 发现与鉴定.

29. Ectopic expression of Nav1.7 in spinal dorsal horn neurons induced by NGF contributes to neuropathic pain in a mouse spinal cord injury model.

30. Naked Mole-Rats Demonstrate Profound Tolerance to Low Oxygen, High Carbon Dioxide, and Chemical Pain.

31. Nav1.7 P610T mutation in two siblings with persistent ocular pain after corneal axon transection: impaired slow inactivation and hyperexcitable trigeminal neurons.

32. 20S-Ginsenoside Rh2, the major bioactive saponin in Panax notoginseng flowers, ameliorates cough by inhibition of NaV1.7 and TRPV1 channel currents and downregulation of TRPV1 expression.

33. Stem cell-derived sensory neurons modelling inherited erythromelalgia: normalization of excitability.

34. Polysorbate 80 blocked a peripheral sodium channel, Nav1.7, and reduced neuronal excitability.

35. Nav1.7、Nav1.8 和交感芽生在大鼠 SNI 模型神经 病理性疼痛形成过程中的作用.

36. Polygodial, a drimane sesquiterpenoid dialdehyde purified from Drimys winteri, inhibits voltage-gated sodium channels.

37. Reversal of Peripheral Neuropathic Pain by the Small-Molecule Natural Product Narirutin via Block of Na v 1.7 Voltage-Gated Sodium Channel.

38. Multifactorial pathways in burn injury-induced chronic pain: novel targets and their pharmacological modulation.

39. [ Tougu Xiaotong Capsule alleviates cartilage degeneration in mice with knee osteoarthritis by modulating Nav1.7].

40. Nav1.7 is required for normal C-low threshold mechanoreceptor function in humans and mice.

41. Lidocaine reduces pain behaviors by inhibiting the expression of Nav1.7 and Nav1.8 and diminishing sympathetic sprouting in SNI rats.

42. Prediction and verification of potential lead analgesic and antiarrhythmic components in Corydalis yanhusuo W. T. Wang based on voltage-gated sodium channel proteins.

43. Functional expression of NaV1.7 channels in freshly dispersed mouse bronchial smooth muscle cells.

44. General mechanism of spider toxin family I acting on sodium channel Nav1.7.

45. There is no F in APC: Using physiological fluoride-free solutions for high throughput automated patch clamp experiments.

46. Unwinding and spiral sliding of S4 and domain rotation of VSD during the electromechanical coupling in Nav1.7.

47. Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of NaV1.7.

48. Cell specific regulation of NaV1.7 activity and trafficking in rat nodose ganglia neurons

49. Fifteen years of NaV1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?

50. Examination of the contribution of Nav1.7 to axonal propagation in nociceptors.